Overview

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Status:
Recruiting

Trial end date:
2027-01-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Acalabrutinib
Obinutuzumab
Venetoclax